Xinlei Mi

Northwestern University

Papers

1

Total Citations

36

H-Index

1

About

Dr. Xinlei Mi is a rising leader in urological surgery, with a focused expertise in minimally invasive treatments for benign prostatic hypertrophy (BPH). His most impactful work, a 2022 comparative outcomes study, rigorously evaluates three major surgical approaches for large-gland BPH: holmium laser enucleation (HoLEP), open simple prostatectomy, and robotic simple prostatectomy. This research, which has garnered 36 citations in just a few years, provides critical, evidence-based guidance for surgeons choosing between these techniques, directly influencing clinical decision-making for patients with enlarged prostates. By systematically analyzing perioperative outcomes, complications, and functional recovery, Dr. Mi’s work helps define the optimal balance between efficacy and invasiveness. His contributions are particularly valuable in an era where robotic and laser technologies are rapidly evolving, offering a clear, data-driven comparison that aids both surgical training and patient counseling. Dr. Mi’s research is essential reading for urologists and residents seeking to understand the modern landscape of BPH surgery, establishing him as a key voice in advancing patient-centered, outcomes-focused urological care.

Research Focus

Key Achievements

1
H-Index
1
Papers
36
Total Citations
36
Avg Citations/Paper
🏆 Most Cited Paper
An Outcomes Comparison Between Holmium Laser Enucleation of the Prostate, Open Simple Prostatectomy, and Robotic Simple Prostatectomy for Large Gland Benign Prostatic Hypertrophy
36 citations · 2022
📈 Most Prolific Year: 2022 (1 Papers)
🤝 Key Collaborators: 7
🏛 Institutions: Northwestern University

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago